Despite the increasingly unpredictable nature of COVID-19, our commitment to provide educational resources and networking experiences to keep pharmaceutical knowledge thriving and the industry moving forward has not wavered.
Therefore, we are very excited to announce that the JAK Inhibitors Drug Development Summit has been transformed into an exclusive one-day digital event that will immerse you in discussions on developing the next generation of JAK inhibitors to expand their clinical utility across oncology, dermatology and autoimmune disease indications.
This is your one and only cross-disciplinary JAK inhibitor meeting with all the content and networking opportunities now delivered in a digital format.
Our community of JAK inhibitor experts are looking forward to connecting with you in the digital world, including:
- Leandro Santos, Associate Director, Clinical Sciences Incyte
- Maciej Wieczorek, Chief Executive Officer, Celon Pharma
- Piet Wigerinck, Chief Scientific Officer, Galapagos
- Anabela Cardoso, Global Brand Development, Lead – Immunology, Eli Lilly
- Brett King, Associate Professor of Dermatology, Yale School of Medicine
- Massimo Gadina, Chief Translational Immunology Section, National Institute of Arthritis & Musculoskeletal & Skin Diseases
Don’t miss this opportunity to hear about the latest data shared by peers, and take advantage of the online networking and ‘Ask the Expert Speaker’ chatrooms.
Visit the website to learn more and secure your place: https://ter.li/o6ghqw